News

Of the original 20 patients enrolled at the nab-paclitaxel 100mg/m2 dose, 17 had levels of CA 19-9 that could be evaluated. CA 19-9 levels dropped more than 20%

According to PharmaTimes, the FDA has asked Pfizer to suspend the 30-second online video advertisement for Viagra (sildenafil), which appeared on CNN.com. FDA believes that Pfizer’s ad has

According to the firm’s annual drug trend report, the average copayment paid by insured patients fell down to $13.20 in 2007 from $13.45 in 2006, even though the

The company recently unveiled a cream which is formulated to provide lasting pain relief. Stopain Cream incorporates Invisicare, an extended-release polymer technology that works on contact, rapidly and

The Iota-Beactica platform couples comprehensive, site-directed fragment-based drug discovery (FBDD) libraries to state-of-the-art fragment and lead screening using surface plasmon resonance (SPR) biosensor technology, enabling the rapid progression

Analyses of 12-month interim antibody data in the first 125 patients randomized in the study indicate that for all patients treated with 900mg, 300mg, or 100mg of Riquent

The median overall survival rate was 27 weeks and both this efficacy and the safety profile compares favorably with current medical treatments which often include palliative best supportive

The lead compound, which is positioned for clinical trials within a year, targets a key mechanism that determines whether cells, particularly those in tumors, grow and proliferate. Dale

IDX184 is a nucleotide prodrug derived from Idenix’s proprietary liver- targeting technology. Results from in vitro and in vivo preclinical studies confirm that this technology preferentially activates IDX184